Perioperative Risk, Anesthesia, Critical Care, and Readmissions
Perioperative risk, anesthesia choice, critical-care planning, and readmission prevention in major vascular surgery. The chapter frames cardiac, pulmonary, renal, bleeding, and functional risk as inputs that can change the operative plan rather than as boxes to clear before incision.
Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.
General medical education, not patient-specific advice.
Choose the hostsPreoperative risk stratification and pathways
Major vascular operations are elevated-risk procedures requiring formal risk stratification rather than empiric clearance. Contemporary guidelines define a stepwise approach incorporating clinical risk indices, functional capacity expressed in metabolic equivalents, and targeted biomarker or stress testing when the results alter management . Functional capacity below 4 METs, the inability to climb two flights of stairs or walk on level ground at 4 mph, defines poor functional capacity. In a patient with poor or unknown functional capacity and elevated clinical risk, guidelines direct additional biomarker or stress testing only when it will change management. The Revised Cardiac Risk Index maps to common vascular patient characteristics: high-risk surgery, ischemic heart disease, heart failure, cerebrovascular disease, insulin-treated diabetes, and creatinine above 2.0 mg/dL. A score of 0 or 1 predicts low risk, 2 intermediate risk, and 3 or more elevated risk . Because the index was derived before high-sensitivity troponin and natriuretic peptide testing, biomarkers are added when functional capacity is uncertain or the clinical risk is intermediate to high. Vascular-specific risk models provide further calibration for carotid endarterectomy, lower-extremity bypass, and aortic repair .
Functional capacity is measured objectively. Cohort evidence supports relying on tools such as the Duke Activity Status Index, cardiopulmonary exercise testing, or N-terminal pro-brain natriuretic peptide rather than subjective impressions . An elevated preoperative natriuretic peptide, BNP at or above 92 ng/L or NT-proBNP at or above 300 ng/L, predicts substantially increased 30-day risk of death or myocardial injury and supports intensified postoperative troponin surveillance .
Intermediate to elevated clinical risk
- Assessment or pathway element
- Cardiac biomarker or stress testing
- Rationale and evidence
- Supplements standard risk indices when functional capacity is poor or uncertain
CitationOpen aortic repair
- Assessment or pathway element
- Enhanced recovery pathway
- Rationale and evidence
- Coordinates prehabilitation, regional anesthesia, fluid management, early oral intake, and structured drain removal
CitationInfrainguinal bypass
- Assessment or pathway element
- Enhanced recovery pathway
- Rationale and evidence
- Aligns prehabilitation, opioid-sparing analgesia, structured nutrition, and early mobilization
CitationCarotid endarterectomy
- Assessment or pathway element
- Equipoise between local and general anesthesia
- Rationale and evidence
- The GALA trial showed similar 30-day stroke, myocardial infarction, or death rates regardless of anesthetic mode
Citation
Frailty and perioperative medication management
Frailty assessment precedes elective vascular intervention because it predicts complications, prolonged length of stay, readmission, and loss of independence independently of chronological age and conventional cardiac indices . In vascular surgery, frailty is associated with postdischarge mortality and structures shared decision-making rather than serving as a binary operative gate .
Perioperative beta-blocker management is a continuation decision. Established therapy is continued, but routine initiation before surgery is not supported. In the POISE trial, starting high-dose extended-release metoprolol shortly before surgery reduced nonfatal myocardial infarction but increased stroke and total mortality .
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are selectively withheld in patients prone to hypotension. Withholding these agents reduces intraoperative hypotension without increasing major postoperative cardiovascular or kidney events .
Direct oral anticoagulants follow a standardized interruption without heparin bridging or preoperative coagulation testing. Apixaban and rivaroxaban are omitted for 1 day before a low-bleeding-risk procedure and 2 days before a high-bleeding-risk procedure. Dabigatran is dosed by renal function: with CrCl at or above 50 mL/min, hold 1 day before low-risk and 2 days before high-risk surgery; with CrCl below 50 mL/min, hold 2 days before low-risk and 4 days before high-risk surgery. Resume 1 day after low-bleeding-risk surgery and 2 to 3 days after high-bleeding-risk surgery .
| Medication class | Perioperative action | Trial evidence and rationale | Citation |
|---|---|---|---|
| Beta-blockers | Continue established therapy; do not routinely initiate | POISE trial demonstrated reduced MI but elevated stroke and total mortality with routine high-dose initiation | |
| ACE inhibitors and ARBs | Selectively hold in hypotension-prone patients | Withholding reduces intraoperative hypotension without elevating postoperative cardiovascular event risk | |
| Direct oral anticoagulants | Interruption guided by pharmacokinetics, renal function, and bleeding risk | The PAUSE protocol achieved major bleeding below 2% and thromboembolism below 1% without heparin bridging |
- Perioperative action
- Continue established therapy; do not routinely initiate
- Trial evidence and rationale
- POISE trial demonstrated reduced MI but elevated stroke and total mortality with routine high-dose initiation
- Citation
- Perioperative action
- Selectively hold in hypotension-prone patients
- Trial evidence and rationale
- Withholding reduces intraoperative hypotension without elevating postoperative cardiovascular event risk
- Citation
- Perioperative action
- Interruption guided by pharmacokinetics, renal function, and bleeding risk
- Trial evidence and rationale
- The PAUSE protocol achieved major bleeding below 2% and thromboembolism below 1% without heparin bridging
- Citation
Hemodynamics, critical care, and complication tracking
Intraoperative mean arterial pressure targets are individualized to baseline chronic pressure, end-organ reserve, and procedural hemodynamics to minimize the depth and duration of hypotension . Avoid intraoperative MAP below 65 mmHg, and especially below 55 mmHg; the risk of myocardial injury and acute kidney injury climbs with both the depth and the cumulative duration of hypotension . Postoperative intensive care admission is selected based on patient risk, procedural complexity, intraoperative instability, blood loss, and vasopressor requirements rather than blanket unit policies .
Postoperative myocardial injury after noncardiac surgery is largely asymptomatic and carries a strong, graded association with 30-day mortality . In the VISION cohort, peak postoperative high-sensitivity troponin T elevation correlated directly with 30-day mortality: 20 to 64 ng/L yielded 3.0%, 65 to 999 ng/L yielded 9.1%, and >= 1000 ng/L yielded 29.6%, with 93.1% of patients experiencing no ischemic symptoms. Cardiac troponin T elevation above the 99th percentile occurs in approximately 16% of adults aged 45 years or older after inpatient noncardiac surgery, with nearly 90% of events lacking symptoms . Both ischemic and non-ischemic mechanisms contribute to long-term mortality risk .
For patients with myocardial injury after noncardiac surgery, the MANAGE trial demonstrated that dabigatran 110 mg twice daily reduced major vascular complications at two years without a significant increase in major bleeding . Implementation requires weighing this benefit against specific fresh-anastomosis or procedural bleeding risks.
Other major perioperative complications tracked in vascular populations include:
- Postoperative delirium occurs in approximately 20% of noncardiac surgery patients, driven by older age, baseline cognitive impairment, elevated inflammatory markers, and prolonged anesthetic duration .
- Postoperative atrial fibrillation develops in roughly 1% of patients without baseline disease, with preoperative N-terminal pro-brain natriuretic peptide offering independent predictive value .
- Perioperative ischemic stroke confers elevated cardiovascular and neurologic cause-specific mortality .
- Bleeding and transfusion requirements are reduced by pharmacologic antifibrinolytics, though mortality evidence in vascular cohorts remains of low certainty .
Readmission mitigation and follow-up
Readmission after lower-extremity bypass is frequent, with cohort and registry rates between 14% and 18% within 30 days. Wound infection drives 37% of readmission indications, and 75% of readmissions are classified as related and unplanned .
Predictors of 30-day readmission following lower-extremity bypass include:
- Return to the operating room during the index admission.
- Cardiac comorbidity.
- Critical limb ischemia indication.
- Dialysis dependence.
- Malnutrition.
- Dependent functional status.
- Obesity and dyspnea .
For open abdominal aortic aneurysm repair, the transabdominal approach is associated with higher 30-day readmission and long-term reintervention rates compared with the retroperitoneal approach, independent of comparable perioperative mortality .
Care fragmentation elevates non-index readmission rates, particularly for complex aortic patients with longer travel distances to the index hospital . Cohort evidence supports early post-discharge outpatient follow-up to mitigate readmission risk, as a substantial minority of readmissions are potentially avoidable through index-admission optimization, transitional-care escalation, and earlier clinic review .
Areas of controversy
The strength of evidence underlying vascular-specific Enhanced Recovery After Surgery pathways for open aortic and infrainguinal bypass operations remains moderate to weak due to a paucity of high-quality randomized trials in these populations .
While the MANAGE trial supports dabigatran therapy for patients with myocardial injury after noncardiac surgery, balancing this antithrombotic benefit against the bleeding risk of fresh vascular reconstructions, groin incisions, and retroperitoneal dissections remains center-dependent and driven by specific procedural anatomy .
The decision to withhold or continue angiotensin-converting enzyme inhibitors and angiotensin receptor blockers preoperatively lacks uniform consensus, requiring individualized trade-offs between intraoperative hypotension and baseline heart-failure stability or refractory hypertension .
References
- 1.2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. 2024.PubMed-indexed articleClinical practice guideline2024
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. 2024. doi:10.1161/cir.0000000000001285.
- 2.2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. 2022.PubMed-indexed articleClinical practice guideline2022
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. 2022. doi:10.1093/eurheartj/ehac270.
- 3.Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. 1999.PubMed-indexed articleRegistry / cohort1999
Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. 1999. doi:10.1161/01.cir.100.10.1043.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.Frailty and post-operative outcomes in older surgical patients: a systematic review. BMC geriatrics. 2016.PubMed-indexed articleMeta-analysis / systematic review2016
Frailty and post-operative outcomes in older surgical patients: a systematic review. BMC geriatrics. 2016. doi:10.1186/s12877-016-0329-8.
- 10.
- 11.
- 12.
- 13.Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 2008.PubMed-indexed articleRandomized controlled trial2008
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 2008. doi:10.1016/s0140-6736(08)60601-7.
- 14.
- 15.Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024.PubMed-indexed articleRandomized controlled trial2024
Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024. doi:10.1001/jama.2024.17123.
- 16.
- 17.
- 18.
- 19.Intraoperative Hypotension in Patients Having Major Noncardiac Surgery Under General Anesthesia: A Systematic Review of Blood Pressure Optimization Strategies. Anesthesia and analgesia. 2025.PubMed-indexed articleMeta-analysis / systematic review2025
Intraoperative Hypotension in Patients Having Major Noncardiac Surgery Under General Anesthesia: A Systematic Review of Blood Pressure Optimization Strategies. Anesthesia and analgesia. 2025. doi:10.1213/ane.0000000000007074.
- 20.
- 21.
- 22.
- 23.Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. Circulation. 2018.PubMed-indexed articleRegistry / cohort2018
Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. Circulation. 2018. doi:10.1161/circulationaha.117.030114.
- 24.
- 25.Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. 2018.PubMed-indexed articleRandomized controlled trial2018
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. 2018. doi:10.1016/s0140-6736(18)30832-8.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017;33(1):17-32.PubMed-indexed article2017
Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017;33(1):17-32.
- 36.Salmasi V, Maheshwari K, Yang D, et al. Relationship between Intraoperative Hypotension and Acute Kidney and Myocardial Injury after Noncardiac Surgery. Anesthesiology. 2017;126(1):47-65.PubMed-indexed article2017
Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A. Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology. 2017;126(1):47-65.
- 37.Walsh M, Devereaux PJ, Garg AX, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013;119(3):507-515.PubMed-indexed article2013
Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013;119(3):507-515.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.